Airborne particulate matter increases MUC5AC expression by downregulating Claudin-1 expression in human airway cells

Sang-Su Kim1, Cheol Hong Kim2, Ji Wook Kim1

  • 1Department of Anesthesiology and Pain Medicine, Kosin University College of Medicine, Busan 49267, Korea.

BMB Reports
|September 27, 2017
PubMed

Insights

CLB2.0 triggers airway inflammation by increasing MUC5AC and decreasing claudin-1. This process involves reactive oxygen species (ROS) and ERK1/2 activation, impacting mucus homeostasis.

Area of Science:

  • Immunology
  • Cell Biology
  • Respiratory Medicine

Background:

  • CLB2.0, a component of particulate matter, is known to induce airway inflammation.
  • Cytokines and chemokines play critical roles in regulating inflammatory responses in the airways.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which CLB2.0 induces airway inflammation.
  • To investigate the role of interleukin-6 (IL-6), reactive oxygen species (ROS), and ERK1/2 mitogen-activated protein kinase (MAPK) pathway in CLB2.0-mediated responses.
  • To examine the impact of CLB2.0 on tight junction proteins, specifically claudin-1, and mucin expression (MUC5AC and MUC1).

Main Methods:

  • Cell culture experiments to assess cytokine and chemokine secretion.
  • Western blotting and quantitative PCR to measure protein and gene expression of mucins and tight junction proteins.
  • Measurement of ROS production using fluorescent probes.
  • Pharmacological inhibition of ROS and MAPK pathways.

Main Results:

  • CLB2.0 induced the secretion of IL-6, which upregulated MUC5AC and MUC1 expression.
  • CLB2.0 inhibited claudin-1 expression; overexpression of claudin-1 decreased MUC5AC but increased MUC1 expression.
  • IL-6 secretion was dependent on ROS, and N-acetylcysteine (ROS scavenger) inhibited IL-6 and MUC5AC expression while increasing MUC1 expression.
  • CLB2.0 activated ERK1/2 MAPK via a ROS-dependent pathway. ERK1/2 activation downregulated claudin-1 and MUC1 but increased MUC5AC expression.

Conclusions:

  • CLB2.0-induced ERK1/2 activation acts as a switch regulating airway inflammation through a ROS-dependent pathway.
  • Secreted IL-6, via ROS-mediated downregulation of claudin-1, influences MUC5AC and MUC1 expression to maintain airway mucus homeostasis.

Related Concept Videos

Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
744
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.9K
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
1.2K